Monday, October 23, 2017 7:01:55 PM
October 18, 2017) - Savara, Inc. (SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today reported that patient enrollment is now complete in a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial of Aironite, a sodium nitrite solution for inhalation via nebulization, in patients with heart failure with preserved ejection fraction (HFpEF). The 100-patient study, known as the Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF (INDIE-HFpEF) study, is sponsored by Duke Clinical Research Institute (DCRI) as the Coordinating Center for the Heart Failure Clinical Research Network (HFN) and is being conducted at various clinical centers that are part of the HFN. Savara expects that top-line results from the INDIE-HFpEF study will be available in the first half of 2018.
Recent SVRA News
- Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 • Business Wire • 04/08/2024 12:05:00 PM
- Savara Announces New Employment Inducement Grant • Business Wire • 03/22/2024 08:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 09:26:08 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:05:33 PM
- Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update • Business Wire • 03/07/2024 09:05:00 PM
- Savara to Present at the Barclays 26th Annual Global Healthcare Conference • Business Wire • 03/06/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 01:31:02 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 01:35:51 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:15:14 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 02:00:11 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/07/2024 01:01:53 PM
- Savara Announces New Employment Inducement Grant • Business Wire • 02/02/2024 01:05:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/01/2024 08:50:25 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/31/2024 07:08:28 PM
- Savara to Present at Two Upcoming Healthcare Conferences • Business Wire • 01/31/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:06:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 01:00:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 09:35:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 09:34:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 09:33:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/28/2023 09:29:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/28/2023 09:15:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/28/2023 09:10:13 PM
- Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) • Business Wire • 12/21/2023 01:05:00 PM
- Savara Added to the NASDAQ Biotechnology Index • Business Wire • 12/20/2023 01:05:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM